Applied Therapeutics Inc

-2.07 (-13.19%)
Earnings Announcements

Applied Therapeutics Says On Track To Submit NDA For AT-007 in Galactosemia

Published: 03/18/2021 11:13 GMT
Applied Therapeutics Inc (APLT) - Applied Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results.
Applied Therapeutics Inc - on Track to Submit NDA for At-007 in Galactosemia No Later Than Q3 2021; Commercial Preparations Underway.
Applied Therapeutics - Arise-hf Phase 3 Global Registrational Study of At-001 in Diabetic Cardiomyopathy on Track to Complete Enrollment in Mid-2021.
Applied Therapeutics - on Track to Initiate Rare Disease Franchise Expansion Programs in Sord Deficiency and Pmm2-cdg Studies in First Half of 2021.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$1.15

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.20

More details on our Analysts Page.